Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karla C Fischer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cell Death & Disease|January 8, 2021
Deletion of IKK2 in haematopoietic cells of adult mice leads to elevated interleukin-6, neutrophilia and fatal gastrointestinal inflammationKarla C Fischer, Carmel P Daunt, Cédric S Tremblay, et al.
Blood Neoplasia|October 27, 2025
MNT: a new target for AMLKarla C Fischer, Veronique Litalien, Sarah T Diepstraten, et al.
Cell Death and Differentiation|April 6, 2024
A novel inhibitory BAK antibody enables assessment of non-activated BAK in cancer cellsHema Preethi Subas Satish, Sweta Iyer, Melissa X Shi, et al.
Cancer Cell|April 26, 2024
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancersSarah T Diepstraten, Yin Yuan, John E La Marca, et al.
Blood Advances|October 20, 2020
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML modelsEmma Morrish, Anthony Copeland, Donia M Moujalled, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cell Death & Disease|January 8, 2021
Deletion of IKK2 in haematopoietic cells of adult mice leads to elevated interleukin-6, neutrophilia and fatal gastrointestinal inflammationKarla C Fischer, Carmel P Daunt, Cédric S Tremblay, et al.
Blood Neoplasia|October 27, 2025
MNT: a new target for AMLKarla C Fischer, Veronique Litalien, Sarah T Diepstraten, et al.
Cell Death and Differentiation|April 6, 2024
A novel inhibitory BAK antibody enables assessment of non-activated BAK in cancer cellsHema Preethi Subas Satish, Sweta Iyer, Melissa X Shi, et al.
Cancer Cell|April 26, 2024
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancersSarah T Diepstraten, Yin Yuan, John E La Marca, et al.
Blood Advances|October 20, 2020
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML modelsEmma Morrish, Anthony Copeland, Donia M Moujalled, et al.
Pageof 1